Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA

MODERNA, INC.

(MRNA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/23/2021 02/24/2021 02/25/2021 02/26/2021 03/01/2021 Date
150.17(c) 144.79(c) 148.38(c) 154.81(c) 147.35 Last
15 509 168 9 757 204 15 172 131 13 445 239 4 222 947 Volume
-5.77% -3.58% +2.48% +4.33% -4.82% Change
More quotes
Financials (USD)
Sales 2021 16 474 M - -
Net income 2021 8 798 M - -
Net cash position 2021 13 038 M - -
P/E ratio 2021 7,12x
Yield 2021 -
Sales 2022 13 137 M - -
Net income 2022 5 654 M - -
Net cash position 2022 18 931 M - -
P/E ratio 2022 11,2x
Yield 2022 -
Capitalization 61 888 M 61 888 M -
EV / Sales 2021 2,97x
EV / Sales 2022 3,27x
Nbr of Employees 1 300
Free-Float 90,0%
More Financials
Company
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows: - Collaboration revenue (79.8%); - Grant revenue (20.2%). At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and... 
Sector
Biotechnology & Medical Research
Calendar
03/01 | 08:00amPresentation
More about the company
Notations Surperformance© of Moderna, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MODERNA, INC.
10:20aGLOBAL MARKETS LIVE: Berkshire Hathaway, Johnson & Johnson, AstraZeneca…
10:05aJ&J CEO sees COVID-19 shots in American arms in 1-2 days as shipping starts
RE
08:08aJOHNSON & JOHNSON  : J&J Covid-19 Vaccine to Start Arriving as Soon as Tuesday, ..
DJ
08:01aFlowserve supplying pumps, valves for Pfizer vaccine production
RE
07:41aHungary stretches vaccine supply to counter "exponential" rise in cases
RE
07:30aASTRAZENECA  : sold out of vaccine maker Moderna last year
RE
07:25aMODERNA  : Chardan Adjusts Moderna's Price Target to $182 From $107, Keeps Buy R..
MT
04:49aASTRAZENECA  : Sells Stake in Moderna for More Than $1 Billion -The Times of Lon..
DJ
04:43aHomebuilders, miners push British stocks higher
RE
03:26aMODERNA  : Orban chooses to receive Chinese jab to boost trust in non-EU vaccine..
AQ
02/28MARKET CHATTER : AstraZeneca Sells Moderna Stake for $1.2 Billion
MT
02/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
02/28Johnson & Johnson's Covid-19 Vaccine Gets Green Light From CDC -- 3rd Update
DJ
02/28JOHNSON & JOHNSON  : CDC Director Signs Recommendation for J&J Covid-19 Vaccine ..
DJ
02/28JOHNSON & JOHNSON  : U.S. Vaccine Panel Recommends J&J Covid-19 Vaccine for Adul..
DJ
More news
News in other languages on MODERNA, INC.
10:46aCORONA-ENTSCHEIDUNGEN :  Habeck warnt vor vorschnellen Lockerungen
10:01aEU-Kommissarin fordert mehr Tempo beim Corona-Impfen
09:21aLes valeurs à suivre aujourd'hui à Wall Street Lundi 1er mars 2021
08:50aMODERNA  : AstraZeneca a vendu sa participation en 2020
08:15aASTRAZENECA  : vendió su participación en Moderna el año pasado
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Stock Trading Strategies
MODERNA, INC. - 2020
The beginning of the move
BUY
More Stock Trading Analysis
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 167,50 $
Last Close Price 154,81 $
Spread / Highest target 34,4%
Spread / Average Target 8,20%
Spread / Lowest Target -48,3%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.48.19%61 888
LONZA GROUP AG0.88%46 924
IQVIA HOLDINGS INC.7.60%36 971
CELLTRION, INC.-17.13%35 993
SEAGEN INC.-13.72%27 376
HANGZHOU TIGERMED CONSULTING CO.,LTD-13.01%18 684